Bayer tests Nexavar against lung cancer in Phase III
June 1st, 2009
Bayer and Onyx Pharmaceuticals have started a late-stage trial testing its drug hopeful Nexavar on lung tumours in a fresh attempt to get the treatment approved against the most common cancer form.
The study in the third and last phase of testing usually required for regulatory clearance will involve about 850 lung cancer patients who could not be helped by two or three previous treatments, the companies said on Monday.